Tetragon Financial Group — Stronger NAV returns, but discount remains wide

Tetragon Financial Group (LSE: TFG)

Last close As at 20/12/2024

USD12.70

0.00 (0.00%)

Market capitalisation

USD1,775m

DISCLAIMER

Please read the Terms of Use below carefully.

You must accept these terms before you can proceed to content on Tetragon Financial Group.

Restrictions on Ownership by US Persons

Tetragon’s shares have not been and will not be registered under the United States Securities Act of 1933. Consequently, Tetragon shares may not be offered, sold or otherwise transferred within the United States or to, or for the account or benefit of, ‘US persons’ as defined in Regulation S under the Securities Act absent registration or an exemption from registration under the Securities Act. No public offering of any Tetragon shares is being, or has been, made in the United States.

In addition, Tetragon has not been and will not be registered under the United States Investment Company Act of 1940. Direct or indirect beneficial ownership of securities issued by Tetragon to any US person who is not a ‘qualified purchaser’ as defined in the Investment Company Act and applicable rules thereunder is prohibited. Under Tetragon’s Articles of Incorporation, the directors of Tetragon may in certain circumstances compel the transfer of any Tetragon shares owned directly or beneficially by any person who is not a ‘qualified purchaser’.

Ownership by Persons in Europe

Tetragon’s non-voting shares are not intended for European retail investors. Tetragon anticipates that its typical investors will be institutional and professional investors who wish to invest for the long term and who have experience in investing in financial markets and collective investment

undertakings and are capable themselves of evaluating the merits and risks of Tetragon shares and who have sufficient resources both to invest in potentially illiquid securities and to be able to bear any losses (which may equal the whole amount invested) that may result from the investment.

More on Tetragon Financial Group

View All

Latest from the Investment Companies sector

View All Investment Companies content

Research: Healthcare

Hutchison China MediTech — Onwards and upwards

Hutchison China MediTech (HCM) continues to make progress towards its global strategic aspirations. The interim results highlight the opportunities for Elunate (fruquintinib) capsules in China, with potential inclusion in China’s exclusive NRDL list in Q419, and the breadth of clinical and regulatory catalysts that lie ahead for multiple R&D assets. Surufatinib’s China NDA submission is on track (Q419) and approval in NET would seal HCM’s position as a premier, innovative, China-based oncology company. The years 2021–22 are pivotal; partner AstraZeneca (AZN) could launch savolitinib in China for NSCLC (MET exon 14) and it could become HCM’s first asset to launch globally (2022) in combination with Tagrisso for NSCLC (c-Met +ve). Given the recent underperformance of the shares and the real potential for HCM to become a global oncology player, we believe it is appropriate to revisit the shares. We value HCM at $5.7bn.

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free